Skip to main content

Invivyd, Inc.

corporate_fare Company Profile

Invivyd, Inc.

IVVD·NASDAQ·Life Sciences·CIK 0001832038

Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody (mAb) therapies to prevent and treat serious viral infectious diseases. The company focuses on providing protection from these diseases, starting with SARS-CoV-2, the virus responsible for COVID-19. PEMGARDA® (pemivibart) is Invivyd's first mAb to receive regulatory authorization. On March 22, 2024, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for PEMGARDA injection, for intravenous (IV) use. This investigational mAb is authorized for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to specific medical conditions or immunosuppressive medications/treatments, and are unlikely to develop an adequate immune response to COVID-19 vaccination. Recipients must not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. The emergency use of PEMGARDA is authorized for the duration of the declaration justifying emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. The company aims to expand its mAb development into other high-need indications, such as respiratory syncytial virus (RSV) and measles.

Invivyd, Inc. (NASDAQ:IVVD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IVVD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for IVVD spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Invivyd 10-Q: $126.4M Cash, Going-Concern Doubt, Nasdaq Bid Notice
  • Invivyd Q3 Loss Widens to $33.5M; DECLARATION Data Now 'Imminent' After FDA Talks
  • Invivyd Posts $33.5M Q3 Loss, $15.4M Revenue as Cash Concerns Linger
  • VYD2311's Superior Safety in Phase 3 LIBERTY Paves Way for BLA Filing
  • Invivyd's VYD2311 Shows Superior Safety vs mRNA Vaccine, BLA Filing Planned

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$53.43M
Net Income
-$52.49M
Diluted EPS
-$0.30
Op. Cash Flow
-$58.13M
Free Cash Flow
-$58.29M
Operating Income
-$55.56M
Cash & Equivalents
$226.69M
Debt / Equity
0.00×
Net Margin
-98.2%
Shares Outstanding
281.99M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092547

Short Interest & Short Volume

9.66 days to cover

FINRA reported short interest of 36,204,545 shares in IVVD as of the October 30, 2026 settlement, a 2.3% decrease from the prior period — about 9.7 days to cover at its recent average daily volume. On November 20, 2026, 44.0% of IVVD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)36,204,545 shares as of October 30, 2026
Change vs prior period▼ 2.3%
Days to cover9.66 at avg daily volume of 3,748,702
Daily short volume (FINRA facilities)44.0% of 3,022,167 shares on November 20, 2026
5-day average short volume59.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$0.43 +4.19% today
52-week range · as of 2026-11-16 $0.43 – $3.07
Market cap
$122.01M
Volume
5.3M (1.3× avg)
3-mo avg 4M
Live data · 2026-11-21 18:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IVVD - Latest Insights

IVVD
Nov 16, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.5867
Real-time Price: $0.430 info
Change: -$0.1567 (-27%) info
Market Cap: $122.007M info
IVVD
Nov 16, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.562
Real-time Price: $0.430 info
Change: -$0.132 (-23%) info
Market Cap: $122.007M info
IVVD
Nov 16, 2026, 7:02 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.5731
Real-time Price: $0.430 info
Change: -$0.1431 (-25%) info
Market Cap: $122.007M info
IVVD
Sep 29, 2026, 7:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9635
Real-time Price: $0.430 info
Change: -$0.5335 (-55%) info
Market Cap: $122.007M info
IVVD
Sep 29, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.430 info
Change: -$0.7298 (-63%) info
Market Cap: $122.007M info
IVVD
Sep 01, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9303
Real-time Price: $0.430 info
Change: -$0.5003 (-54%) info
Market Cap: $122.007M info
IVVD
Aug 13, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.666
Real-time Price: $0.430 info
Change: -$0.236 (-35%) info
Market Cap: $122.007M info
IVVD
Aug 13, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.661
Real-time Price: $0.430 info
Change: -$0.231 (-35%) info
Market Cap: $122.007M info
IVVD
Jul 24, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6114
Real-time Price: $0.430 info
Change: -$0.1814 (-30%) info
Market Cap: $122.007M info
IVVD
Jul 06, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8402
Real-time Price: $0.430 info
Change: -$0.4102 (-49%) info
Market Cap: $122.007M info
IVVD
Jun 16, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.880
Real-time Price: $0.430 info
Change: -$0.450 (-51%) info
Market Cap: $122.007M info
IVVD
Jun 09, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.430 info
Change: -$0.620 (-59%) info
Market Cap: $122.007M info
IVVD
Jun 01, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.17
Real-time Price: $0.430 info
Change: -$0.740 (-63%) info
Market Cap: $122.007M info
IVVD
May 14, 2026, 7:18 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $0.430 info
Change: -$0.990 (-70%) info
Market Cap: $122.007M info
IVVD
May 14, 2026, 7:12 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $0.430 info
Change: -$0.970 (-69%) info
Market Cap: $122.007M info
IVVD
May 14, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $0.430 info
Change: -$0.970 (-69%) info
Market Cap: $122.007M info
IVVD
Apr 09, 2026, 7:13 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $0.430 info
Change: -$0.8836 (-67%) info
Market Cap: $122.007M info
IVVD
Apr 09, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $0.430 info
Change: -$0.870 (-67%) info
Market Cap: $122.007M info
IVVD
Mar 05, 2026, 7:20 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.76
Real-time Price: $0.430 info
Change: -$1.33 (-76%) info
Market Cap: $122.007M info
IVVD
Mar 05, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.76
Real-time Price: $0.430 info
Change: -$1.33 (-76%) info
Market Cap: $122.007M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets